<p>羅氏控股公司：</p>
<ul>
<li>羅氏第三階段 EVERA 數據表明，Giredestrant 顯著改善了雌激素受體陽性晚期乳腺癌患者的無進展生存期</li>
</ul>

羅氏(ADR)

<p>羅氏控股公司：羅氏第三階段 EVERA 數據表明，Giredestrant 顯著改善了雌激素受體陽性晚期乳腺癌患者的無進展生存期</p>

<p>Roche Holding AG :</p>
<div class="lb-trans"><p>羅氏控股公司：</p>
</div><ul>
<li>ROCHE’S PHASE III EVERA DATA SHOWED GIREDESTRANT SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN PEOPLE WITH ER-POSITIVE ADVANCED BREAST CANCER</li>
</ul>
<div class="lb-trans"><ul>
<li>羅氏第三階段 EVERA 數據表明，Giredestrant 顯著改善了雌激素受體陽性晚期乳腺癌患者的無進展生存期</li>
</ul>
</div>

Roche’s Phase III Evera Data Showed Giredestrant Significantly Improved Progression-Free Survival In People With Er-Positive Advanced Breast Cancer